Biopolítica y género : el caso de China

La biopolítica y el género son dos conceptos perfectamente aplicables a las sociedades actuales en las que el poder sigue ejerciendo un control de los cuerpos en función de sus intereses. China es un claro ejemplo de la vigencia de esta forma de opresión que se ejerce principalmente sobre los cuerpos femeninos. Dados los beneficios que la industria cosmética y la industria sexual están aportando a las arcas nacionales Chinas, el modelo de feminidad está cambiando para servir a los intereses del mercado. Los medios de comunicación son los principales creadores de una identidad femenina basada en el culto al cuerpo y en el retorno de valores de la feminidad tradicional que se creían superados. Esta nueva tendencia funciona como un mecanismo de control realmente eficaz que centra los intereses y las preocupaciones de las mujeres únicamente en la estética para frenar su posible potencial de lucha por conseguir la liberación y la igualdad real. Al asociar el ideal de belleza con el placer sexual, la aceptación por parte de las mujeres es mucho mayor, y por tanto se consigue penetrar en sus mentes y modificar el imaginario colectivo para generar en las mujeres una sensación de empoderamiento y libertad poco homologable con la realidad

Odnos broja somatskih stanica i sastav i koagulacijska svojstva ovčjeg mlijeka

The relationship between somatic cell count (SCC) and raw milk composition and its coagulation properties measured at native or standardised pH values were investigated in Manchega ewes’ milk. A total of 84 bulk tank milk samples from flocks included in the National Association of Manchega Sheep Breeders were used. According to their SCC, milk samples were divided into three terciles named low (562±138 cells/mL), medium (956±115 cells/mL) and high (1705±428 cells/ mL) SCC groups. Within each SCC group, two pH treatments were applied before determining coagulation properties (rennet clotting time, curd firming time and curd firmness): no acidification of milk (coagulation at native pH) and acidification of milk at pH 6.5. Native milk pH significantly increased (P0.05) by SCC, protein content tended to be higher in the high SCC group (P=0.05) and lactose content was significantly lower (P0,05) na udjel masti, dok je udjel proteina bio veći u grupi s visokim BSS (P=0,05), a udjel laktoze bio je signifikantno niži (P<0,05) u toj skupini. Kod prirodne pH vrijednosti mlijeka, visoki BSS utjecao je na duže vrijeme zgrušavanja mlijeka sirilom, sporije učvršćivanje gruša i na manju čvrstoću gruša nakon 30 min od dodatka sirila, u odnosu na skupinu u kojoj je BSS bio nizak i srednji (P<0,05). Standardizacija pH mlijeka na 6,5 prije dodavanja sirila anulirala je (P<0,05) negativan utjecaj visokog BSS na koagulacijska svojstva mlijeka. Može se zaključiti da su, unatoč činjenici kako je acidifikacija mlijeka prije zgrušavanja poboljšala koagulacijske osobine mlijeka s visokim BSS, daljnja istraživanja potrebna kako bi se utvrdila senzorska svojstva sira proizvedenog takvim postupkom

Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis

Lleixa and Caballero-avila et al. report that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis. Multiple sclerosis is a tissue-specific autoimmune disease of the central nervous system in which the antigen(s) remains elusive. Antibodies targeting the flotillin-1/2 complex have been described in 1-2% of the patients in a recent study. Other candidate antigens as anoctamin-2 or neurofascin-155 have been previously described in multiple sclerosis patients, although their clinical relevance remains uncertain. Our study aims to analyse the frequency and clinical relevance of antibodies against neurofascin-155, anoctamin-2 and flotillin-1/2 complex in multiple sclerosis. Serum (n = 252) and CSF (n = 50) samples from 282 multiple sclerosis patients were included in the study. The control group was composed of 260 serum samples (71 healthy donors and 189 with other neuroinflammatory disorders). Anti-flotillin-1/2, anti-anoctamin-2 and anti-neurofascin-155 antibodies were tested by cell-based assays using transfected cells. We identified six multiple sclerosis patients with antibodies against the flotillin-1/2 complex (2.1%) and one multiple sclerosis patient with antibodies against anoctamin-2 (0.35%). All multiple sclerosis patients were negative for anti-neurofascin-155 antibodies. Three of the anti-flotillin-1/2 positive patients showed anti-flotillin-1/2 positivity in other serum samples extracted at different moments of their disease. Immunoglobulin G subclasses of anti-flotillin-1/2 antibodies were predominantly one and three. We confirm that antibodies targeting the flotillin-1/2 complex are present in a subgroup of patients with multiple sclerosis. Further studies are needed to understand the clinical and pathological relevance of anti-flotillin-1/2 autoantibodies in multiple sclerosis

Androgen receptor polyQ alleles and COVID-19 severity in men: a replication study

Background: Ample evidence indicates a sex-related difference in severity of COVID19, with less favorable outcomes observed in men. Genetic factors have been proposed as candidates to explain this difference. The polyglutamine (polyQ) polymorphism in the androgen receptor gene has been recently described as a genetic biomarker of COVID-19 severity. Objective: To test the association between the androgen receptor polyQ polymorphism and COVID-19 severity in a large cohort of COVID-19 male patients. Materials and methods: This study included 1136 male patients infected with SARSCoV-2 as confirmed by positive PCR. Patients were retrospectively and prospectively enrolled from March to November 2020. Patients were classified according to their severity into three categories: oligosymptomatic, hospitalized and severe patients requiring ventilatory support. The number of CAG repeats (polyQ polymorphism) at the androgen receptor was obtained by PCR and patients were classified as either short (<23 repeats) or long (≥23 repeats) allele carriers. The association between polyQ alleles (short or long) and COVID-19 severity was assessed by Chi-squared (Chi2) and logistic regression analysis. Results: The mean number of polyQ CAG repeats was 22 (±3). Patients were classified as oligosymptomatic (15.5%), hospitalized (63.2%), and severe patients (21.3%) requiring substantial respiratory support. PolyQ alleles distribution did not show significant differences between severity classes in our cohort (Chi2 test p > 0.05). Similar results were observed after adjusting by known risk factors such as age, comorbidities, and ethnicity (multivariate logistic regression analysis)Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation (COVID-19 Research Call; COV20/00181) co-financed by European Development Regional Fund (FEDER, A way to achieve Europe); Estrella de Levante (E G-N); Colabora Mujer (E G-N); Instituto de Salud Carlos III (Centro de Investigación en Red de Enfermedades Raras, CIBERer); IIS-Fundación Jiménez Díaz-UAM Chair in Genomic Medicine; Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Science and Innovation (Miguel Servet Contract Number: CP17/00006 and Juan Rodes Contract Number: JR17/00020) co-financied by European Regional Development Fund (FEDER); CEGEN-PRB3-ISCIII is funded by ISCIII and ERDF, Grant Number: PT17/001

Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination

[EN] Background: This study compares the severity of SARS-CoV-2 infections caused by Alpha, Delta or Omicron variants in periods of co-circulation in Spain, and estimates the variant-specific association of vaccination with severe disease. Methods: SARS-CoV-2 infections notified to the national epidemiological surveillance network with information on genetic variant and vaccination status were considered cases if they required hospitalisation or controls otherwise. Alpha and Delta were compared during June-July 2021; and Delta and Omicron during December 2021-January 2022. Adjusted odds ratios (aOR) were estimated using logistic regression, comparing variant and vaccination status between cases and controls. Results: We included 5,345 Alpha and 11,974 Delta infections in June-July and 5,272 Delta and 10,578 Omicron in December-January. Unvaccinated cases of Alpha (aOR: 0.57; 95% CI: 0.46-0.69) or Omicron (0.28; 0.21-0.36) had lower probability of hospitalisation vs. Delta. Complete vaccination reduced hospitalisation, similarly for Alpha (0.16; 0.13-0.21) and Delta (June-July: 0.16; 0.14-0.19; December-January: 0.36; 0.30-0.44) but lower from Omicron (0.63; 0.53-0.75) and individuals aged 65+ years. Conclusion: Results indicate higher intrinsic severity of the Delta variant, compared with Alpha or Omicron, with smaller differences among vaccinated individuals. Nevertheless, vaccination was associated to reduced hospitalisation in all groups. [ES]Introducción: El objetivo es comprar la gravedad de las infecciones por las variantes Alfa, Delta y Ómicron del SARS-CoV-2 en periodos de co-circulación en España, y estimar la asociación entre vacunación y gravedad en cada variante. Métodos: Las infecciones por SARS-CoV-2 notificadas a la red nacional de vigilancia epidemiológica con información sobre la variante viral y el estado de vacunación se clasificaron como casos si habían requerido hospitalización, o como controles en caso contrario. Alfa y Delta se compararon durante junio-julio de 2021, y Delta y Ómicron durante diciembre de 2021-enero de 2022. Se estimaron odds ratios ajustadas (ORa) mediante regresión logística, comparando la variante y el estado de vacunación entre casos y controles. Resultados: Se incluyeron 5.345 infecciones por variante Alfa y 11.974 por Delta en junio-julio y 5.272 infecciones por Delta y 10.578 por Ómicron en diciembre-enero. Los casos no vacunados por Alfa (aOR: 0,57; IC 95%: 0,46-0,69) u Ómicron (0,28; IC 95%: 0,21-0,36) tuvieron menor probabilidad de hospitalización comparados con Delta. La vacunación completa se asoció a menor hospitalización de forma similar para Alfa (0,16; IC 95%: 0,13-0,21) y Delta (junio-julio: 0,16; IC 95%: 0,14-0,19; diciembre-enero: 0,36; IC 95%: 0,30-0,44) pero menor para Ómicron (0,63; IC 95%: 0,53-0,75) y para individuos con 65+ años. Conclusión: Los resultados indican una mayor gravedad intrínseca de la variante Delta comparada con Alfa u Ómicron, con menor diferencia entre personas vacunadas. La vacunación se asoció a menor hospitalización en todos los grupos.In this study the identification of variants by genomic sequencing has been partially supported by HERA-Incubator ECDC/GRANT/2021/024-Enhancing Whole Genome Sequencing (WGS) and/or Reverse Transcription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the Covid-19 pandemic in Spain.S

Autoantibody screening in Guillain-Barré syndrome

Background: Guillain?Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain-Barré syndrome. Methods: Autoantibody screening was performed in serum samples from all GBS patients included in the International GBS Outcome study by 11 different Spanish centres. The screening included testing for anti-ganglioside antibodies, anti-nodo/paranodal antibodies, immunocytochemistry on neuroblastoma-derived human motor neurons and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We analysed the staining patterns of patients and controls. The prognostic value of anti-ganglioside antibodies was also analysed. Results: None of the GBS patients (n = 100) reacted against the nodo/paranodal proteins tested, and 61 (61%) were positive for, at least, one anti-ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently than controls both with IgG (6% vs 0%; p = 0.03) and IgM (11% vs 2.2%; p = 0.02) immunodetection. No differences were observed in the proportion of patients reacting against neuroblastoma-derived human motor neurons. Reactivity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed that IgG anti-GM1 antibodies are associated with poorer outcomes independently of other known prognostic factor

Autoantibody screening in Guillain-Barré syndrome

Background: Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy with a heterogeneous presentation. Although some evidences support the role of autoantibodies in its pathogenesis, the target antigens remain unknown in a substantial proportion of GBS patients. The objective of this study is to screen for autoantibodies targeting peripheral nerve components in Guillain-Barré syndrome. Methods: Autoantibody screening was performed in serum samples from all GBS patients included in the International GBS Outcome study by 11 different Spanish centres. The screening included testing for anti-ganglioside antibodies, anti-nodo/paranodal antibodies, immunocytochemistry on neuroblastoma-derived human motor neurons and murine dorsal root ganglia (DRG) neurons, and immunohistochemistry on monkey peripheral nerve sections. We analysed the staining patterns of patients and controls. The prognostic value of anti-ganglioside antibodies was also analysed. Results: None of the GBS patients (n = 100) reacted against the nodo/paranodal proteins tested, and 61 (61%) were positive for, at least, one anti-ganglioside antibody. GBS sera reacted strongly against DRG neurons more frequently than controls both with IgG (6% vs 0%; p = 0.03) and IgM (11% vs 2.2%; p = 0.02) immunodetection. No differences were observed in the proportion of patients reacting against neuroblastoma-derived human motor neurons. Reactivity against monkey nerve tissue was frequently detected both in patients and controls, but specific patterns were only detected in GBS patients: IgG from 13 (13%) patients reacted strongly against Schwann cells. Finally, we confirmed that IgG anti-GM1 antibodies are associated with poorer outcomes independently of other known prognostic factors. Conclusion: Our study confirms that (1) GBS patients display a heterogeneous repertoire of autoantibodies targeting nerve cells and structures; (2) gangliosides are the most frequent antigens in GBS patients and have a prognostic value; (3) further antigen-discovery experiments may elucidate other potential antigens in GBS

Investigar educa en ciudadanía

Este documento recoge los resultados de la segunda parte del proyecto “Educación para el desarrollo basada en investigación y evaluación formativa”, mediante el cual se pretendía incrementar el corpus teórico de la educación para el desarrollo en los ámbitos de didáctica y evaluación.Está publicación ha sido realizada con el apoyo financiero de la Agencia Española de Cooperación Internacional para el Desarrollo (AECID)

Experiències entrecreuades a Santa Eugènia del Congost

Rastres de memòria no escrita. D’experiències entrecreuades a Santa Eugènia del Congost... és el primer d’una sèrie de quaderns de treball amb mostres de material visual recollit en el marc del projecte artístic i didàctic Experiències entrecreuades a Santa Eugènia del Congost, desenvolupat en el context de l’antiga font i safareigs de Santa Eugènia del Congost –situats prop de l’autovia C-17, el riu Congost i de l’Ajuntament de Tagamanent–. Des del curs acadèmic 2016-2017, el Grup d’Innovació Docent Consolidat de la Universitat de Barcelona ATESI (Art, Territori, Estratègia Docent, Sostenibilitat i Intervenció Social – GINDC-UB/162) promou accions –instal·lacions artístiques efímeres, performance, tallers oberts, exposicions i actes...– per tal de «reviure» de forma física i conceptual aquests espais en desús per a la població, tot fent èmfasi en la recuperació de la seva memòria històrica, i amb una metodologia que busca integrar l’actuació conjunta d’administracions, figures expertes, centres educatius i ciutadanes. Aquestes accions, ideològicament posicionades, parteixen del treball en règim d’Aprenentatge Servei (ApS), una metodologia docent que implica l’assoliment de competències educatives en la realització d’activitats que tenen un retorn directe en la comunitat. En aquesta línia, les actuacions dutes a terme que es mostren en aquest quadern han tingut la participació d’alumnat del Grau en Belles Arts de la Universitat de Barcelona, de l’Escola Sagrats Cors de Centelles, de l’Escola d’Art i Superior de Disseny de Vic i d’ex-alumnes del mateix centre (EXARTVIC), coordinat per professorat dels diferents àmbits i amb la participació del Grup ApS(UB)

Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

BACKGROUND AND OBJECTIVES: To study the clinical and laboratory features of antineurofascin-155 (NF155)-positive autoimmune nodopathy (AN). METHODS: Patients with anti-NF155 antibodies detected on routine immunologic testing were included. Clinical characteristics, treatment response, and functional scales (modified Rankin Scale [mRS] and Inflammatory Rasch-built Overall Disability Scale [I-RODS]) were retrospectively collected at baseline and at the follow-up. Autoantibody and neurofilament light (NfL) chain levels were analyzed at baseline and at the follow-up. RESULTS: Forty NF155+ patients with AN were included. Mean age at onset was 42.4 years. Patients presented with a progressive (75%), sensory motor (87.5%), and symmetric distal-predominant weakness in upper (97.2%) and lower extremities (94.5%), with tremor and ataxia (75%). Patients received a median of 3 (2-4) different treatments in 46 months of median follow-up. Response to IV immunoglobulin (86.8%) or steroids (72.2%) was poor in most patients, whereas 77.3% responded to rituximab. HLA-DRB1*15 was detected in 91.3% of patients. IgG4 anti-NF155 antibodies were predominant in all patients; anti-NF155 titers correlated with mRS within the same patient (r = 0.41, p = 0.004). Serum NfL (sNfL) levels were higher in anti-NF155+ AN than in healthy controls (36.47 vs 7.56 pg/mL, p < 0.001) and correlated with anti-NF155 titers (r = 0.43, p = 0.001), with I-RODS at baseline (r = -0.88, p < 0.001) and with maximum I-RODS achieved (r = -0.58, p = 0.01). Anti-NF155 titers and sNfL levels decreased in all rituximab-treated patients. DISCUSSION: Anti-NF155 AN presents a distinct clinical profile and good response to rituximab. Autoantibody titers and sNfL are useful to monitor disease status in these patients. The use of untagged-NF155 plasmids minimizes the detection of false anti-NF155+ cases. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that anti-NF155 antibodies associate with a specific phenotype and response to rituximab